Immunic (IMUX) Free Cash Flow (2013 - 2026)

Immunic has disclosed Free Cash Flow across 14 years of filings, most recently posting -$17.3 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$17.3 million, up 20.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$81.4 million (up 1.7% YoY), and the FY2025 annual result was -$86.0 million, down 1.1% from the prior year.
• Free Cash Flow came in at -$17.3 million for Q1 2026 at Immunic, up from -$19.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$13.7 million in Q3 2022 to a low of -$24.6 million in Q2 2025.
• The 5-year median for Free Cash Flow is -$19.6 million (2023), against an average of -$19.1 million.
• Across the five-year window, Free Cash Flow jumped 45.59% in 2022 and tumbled 61.82% in 2024, its largest moves.
• Immunic's Free Cash Flow stood at -$15.1 million in 2022, then grew by 6.03% to -$14.2 million in 2023, then sank by 61.82% to -$23.0 million in 2024, then climbed by 16.0% to -$19.3 million in 2025, then rose by 10.31% to -$17.3 million in 2026.
• The last three Free Cash Flow figures came in at -$17.3 million (Q1 2026), -$19.3 million (Q4 2025), and -$20.2 million (Q3 2025), per Business Quant data.